Evidence map›Paper›PMID 27171429›Full record

ArticleOcular oncology and pathology2015

SIRT2 Expression Is Higher in Uveal Melanoma than In Ocular Melanocytes.

Danielle G Halfed, Pablo Zoroquiain, Henry A Wood, Paula Blanco, Nouf Al-Saati, Sultan Aldrees, Vasco Bravo-Filho, Miguel N Burnier

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ocular oncology and pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Danielle G HalfedHenry C. Witelson Ocular Pathology Laboratory, Department of Pathology, McGill University, Montreal, Que., Canada.
Pablo ZoroquiainHenry C. Witelson Ocular Pathology Laboratory, Department of Pathology, McGill University, Montreal, Que., Canada.
Henry A WoodHenry C. Witelson Ocular Pathology Laboratory, Department of Pathology, McGill University, Montreal, Que., Canada.
Paula BlancoHenry C. Witelson Ocular Pathology Laboratory, Department of Pathology, McGill University, Montreal, Que., Canada.
Nouf Al-SaatiHenry C. Witelson Ocular Pathology Laboratory, Department of Pathology, McGill University, Montreal, Que., Canada.
Sultan AldreesHenry C. Witelson Ocular Pathology Laboratory, Department of Pathology, McGill University, Montreal, Que., Canada.
Vasco Bravo-FilhoHenry C. Witelson Ocular Pathology Laboratory, Department of Pathology, McGill University, Montreal, Que., Canada.
Miguel N BurnierHenry C. Witelson Ocular Pathology Laboratory, Department of Pathology, McGill University, Montreal, Que., Canada.
McGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSirtuins (SIRTs) are the family of proteins associated with the cell cycle and that correlate with cancer development and progression. SIRTs have never been studied in uveal melanocytes. The aim of this study is to characterize the expression of SIRT2 in uveal melanoma (UM) cases and compare it with the expression of SIRT2 in melanocytes of the uveal tract of normal human eyes (NHE).

methodsTwenty-one formalin-fixed, paraffin-embedded human UM cases were immunostained for SIRT2, along with 15 NHE obtained from the Eye Bank of Canada.

resultsSIRT2 expression was higher in melanomas than in normal melanocytes of both tumor and donor eyes (p < 0.0001). No significant difference in SIRT2 expression was found when comparing normal melanocytes in UM and NHE cases.

conclusionsSIRT2 expression is significantly stronger in UM cells than in normal ocular melanocytes. This finding may indicate an important role of SIRT2 as a prognostic marker in UM progression. SIRT2 should also be investigated as a possible therapeutic target.

Indexed as

Sirtuin 2Uveal melanomaUveal melanoma progression

Identifiers

PMID27171429
PMCPMC4847675
OpenAlexW815213705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.